Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds

Exclusion Criteria

• •1. Patients with severe acute ischemic stroke (NIHSS score ≥21)
• •2. Patients with coma (GCS score \< 8)
• •3. Patients with previous moderate to severe dependence (mRS score 3-5)
• •4. Patients with any contraindications to CT and MRI (such as metal implants, claustrophobia, etc.)
• •5. Patients who are allergic to atorvastatin or excipients
• •6. Patients with intracranial hemorrhagic diseases confirmed by CT or MRI, such as cerebral hemorrhage, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, traumatic cerebral hemorrhage or hemorrhagic conversion of infarcts, etc
• •7. Patients within 6 months after hemorrhagic stroke
• •8. Patients with hemorrhagic tendency, such as abnormal coagulation function, Henoch-Schonlein purpura, platelet count less than 100×109/L or abnormal platelet function, etc
• •9. Patients who are ready to undergo or have undergone intravenous thrombolysis after the onset of the disease or who require urgent or recent (within 90 days) endovascular treatment;
• •10. Patients with severe hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that has not been controlled by treatment
• •11. Patients with hypoglycemia (\< 2.7 mmol/L) or hyperglycemia (\>22.2 mmol/L)
• •12. Patients with previous cerebral arteritis, brain tumor, cerebral parasitic disease, cerebral arteriovenous malformation, cerebral cavernous hemangioma, cerebral aneurysm, severe craniocerebral injury, or intracranial infection
• •13. Patients with previous severe valvular heart disease, atrial fibrillation, acute myocardial infarction or interventional therapy in the past 6 months, heart failure (patients classified as class III-IV according to the New York Heart Association \[NYHA\]) or patients with indications for pacemaker placement but without pacemaker installation or other malignant arrhythmias
• •14. Patients contraindicate to antiplatelet therapy;
• •15. Patients who must use other types of statins or other types of lipid-lowering drugs such as ezetimibe
• •16. Patients with severe mental disorders or dementia that are unable or unwilling to cooperate
• •17. Patients with active liver disease or unexplained 2 or more abnormal liver function tests (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] ≥ 3.0× upper limit of normal \[ULN\])
• •18. Patients with myositis, myopathy, rhabdomyolysis, or 2 or more episodes of unexplained serum creatine kinase\[CK\] elevation (\[CK\]≥5.0×ULN)
• •19. Patients with other serious systemic or organic diseases that investigators believe will not allow evaluation of efficacy or are unlikely to complete the expected course of treatment and follow-up (e.g., malignancy, life expectancy \< 3 years, etc.)
• •20. Women who are pregnant, breastfeeding or planning to become pregnant and who do not want to use contraception
• •21. Patients who participated in or are participating in other clinical trials during the 3 months prior to the study
• •22. Patients who are deemed ineligible for clinical trial participation by the investigator
• •23. Patients or their legal representatives do not consent to participate in this study